JMIR Publications

ABSTRACT

Background:

This study aims to analyze the rapidly evolving ecosystem of Digital Health Applications (DiGA) in Germany, spurred by the 2019 Digital Healthcare Act (DVG). With over 73 million people in Germany now having access to DiGA, these tools represent a substantial stride in healthcare modernization, supporting both patients and healthcare providers with digital solutions for disease management and care improvement.

Objective:

Through a data-driven approach, this research unpacks the complexities of DiGA market dynamics, economic factors, and clinical evidence, offering insights into their impact over the past years.

Methods:

The analysis draws from a range of public data sources, including the DiGA directory, statutory health insurance reports, app store feedback, and clinical study results.

Results:

As of July 1st, 2024, there are 56 DiGA listed by the Federal Institute for Drugs and Medical Devices (BfArM), divided into 35 permanently and 21 preliminarily listed applications. Our findings reveal that a majority of DiGA extend beyond the intended one-year period to achieve permanent listing, reflecting the extensive effort required to demonstrate clinical efficacy. Economic analysis uncovers a dynamic pricing landscape, with initial prices ranging from approximately 200 EUR to 700 EUR, averaging at a median of 514.00 EUR for a three-month DiGA prescription. Following negotiations or arbitration board decisions, prices typically see a 50% reduction, settling at a median of 221.00 EUR. Prescription data offers valuable insights into DiGA acceptance, with total prescriptions jumping from around 41,000 in the first period to 209,000 in the latest reporting period. The analysis of the top 15 DiGA, representing 82% of total prescriptions, shows that these best-performing apps receive from a minimum of eight to a maximum of 77 daily prescriptions, with native apps and early market entrants achieving higher rates. Clinical evidence from all 35 permanently listed DiGA indicates a uniform preference for randomized controlled trials to validate primary endpoints, with no noteworthy use of alternative study designs encouraged in the DVG and the according ordinance. Moreover, all evaluated DiGA focused on medical benefits, with health status improvement as a key endpoint, suggesting an underutilization of patient-relevant structural and procedural improvements (pSVV) in demonstrating healthcare impact.

Conclusions:

This study highlights the growth and challenges within the DiGA sector, suggesting areas for future research such as the exploration of new study designs and the potential impact of pSVV. For DiGA manufacturers, the strategic advantage of early market entry is emphasized. Overall, this paper underscores the evolving landscape of digital health, advocating for a nuanced understanding of digital health technology integration in Germany and beyond.